Clinical Applications of Recombinant Human Granulocyte Colony-Stimulating Factor in Reproductive Medicine: Expert Consensus
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is primarily indicated for neutropenia caused by various etiologies in clinical practice. Recently, it has been shown to have some therapeutic effects and be safe for mother and child in some clinical research and treatment of reproductive diseases. However, until now, there is currently no authoritative expert consensus and guidelines published. To standardize the research and rational application of rhG-CSF in reproductive medicine-related fields, the Committee on Reproductive Immunity of the China Association for Promotion of Health Science and Technology (the Committee) organized experts from relevant disciplines to formulate the Expert Consensus, which is based on the latest international basic study, clinical research evidence, and the national situation of China. According to evidence-based data, recommendations were established on the applicable population, medication methods, and timing of discontinuation of rhG-CSF in reproductive medicine. It is recommended that rhG-CSF could be applied in patients with thin endometrium, which was ineffective to standard treatments, in unexplained recurrent spontaneous abortion (RSA), in unexplained recurrent implantation failure (RIF), and could attempt to be applied in unexplained RSA with the slow rise of human chorionic gonadotropin and embryo growth retardation. After the patient signs the super instruction for medication and treatment informed consent form, rhG-CSF can only be used for patients with thin endometrium, unexplained recurrent miscarriage, unexplained repeated embryo implantation failure, slow rise of human chorionic gonadotropin. Comprehensive communication between gynecologists and obstetricians and patients before therapy is essential according to that the rhG-CSF treatment would be inefficient when a genetic abnormality, embryo abnormality, heterotopic pregnancy and other unknown disorder exist.
Authors and Affiliations
Jianming Chen, Yazhong Ji, Zhaohui Zhang
Keywords
Related Articles
- EP ID EP740146
- DOI 10.54457/DR.202301008
- Views 77
- Downloads 0
ransient Hypopituitarism in a Patient Developing Diabetic Ketoacidosis after COVID-19: Case Report
Since the beginning of the novel coronavirus disease (COVID-19) pandemic, many papers have been published about the association between COVID-19 and various endocrine abnormalities. Accumulated data so far reveal that hy...
A Review on Cancer Cell Metabolism of Fats: Insights into Altered Lipid Homeostasis
The dysregulation of fat metabolism is a key characteristic of cancer cells, contributing to their survival, growth, and metastatic potential. Mutations in genes involved in fat metabolism pathways have been identified w...
HBeAg Negativity is Associated with a Higher Risk of Liver-Related Death in Patients with Chronic Hepatitis B Related Liver Cirrhosis
Background and aims Few studies reported the association between the survival of patients with chronic hepatitis B (CHB)-related liver cirrhosis (LC) and hepatitis B e antigen (HBeAg) state. Methods Three hundred and ni...
Efficacy of Platelet-Rich Plasma Combined with Wen Shen Formula in the Treatment of Thin Endometrium-Related Infertility
Objective To explore the effectiveness of Platelet-Rich Plasma (PRP) combined with Wen Shen Formula in treating thin endometrium. Methods From January 2019 to January 2023, 90 patients with thin endometrium-related infe...
Clinical Progress of Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Concurrent chemoradiotherapy (CCRT) is the foundational standard-of-care for patients with locoregionally advanced nasopharyngeal carcinoma (LANPC). Adding adjuvant chemotherapy (AC) or induction chemotherapy (IC) to CCR...